Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial

Twelves, C, Cortés, J, Shaughnessy, JO et al. (16 more authors) (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial. European Journal of Cancer, 76. pp. 205-215. ISSN 0959-8049

Abstract

Metadata

Authors/Creators:
  • Twelves, C
  • Cortés, J
  • Shaughnessy, JO
  • Awada, A
  • Perez, EA
  • Im, SA
  • Gómez-Pardo, P
  • Schwartzberg, LS
  • Diéras, V
  • Yardley, DA
  • Potter, DA
  • Mailliez, A
  • Moreno-Aspitia, A
  • Ahn, J-S
  • Zhao, C
  • Hoch, U
  • Tagliaferri, M
  • Hannah, AL
  • Rugo, HS
Copyright, Publisher and Additional Information: © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Advanced breast cancer; Etirinotecan pegol; Metastatic breast cancer; NKTR-102; Quality of life
Dates:
  • Published: May 2017
  • Accepted: 6 February 2017
  • Published (online): 27 March 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 31 Mar 2017 09:19
Last Modified: 05 Oct 2017 16:24
Published Version: https://doi.org/10.1016/j.ejca.2017.02.011
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.ejca.2017.02.011

Share / Export

Statistics